Literature DB >> 17325603

Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.

Judith C Shlay1, Glenn Bartsch, Grace Peng, Jack Wang, Carl Grunfeld, Cynthia L Gibert, Fehmida Visnegarwala, Sai Subhasree Raghavan, Ying Xiang, Martha Farrough, Harold E Perry, Donald Kotler, Wafaa M El-Sadr.   

Abstract

OBJECTIVE: To assess changes in metabolic parameters and body composition among 422 antiretroviral-naive patients randomized to 3 antiretroviral therapy (ART) strategies: protease inhibitor (PI; n = 141)-, nonnucleoside reverse transcriptase inhibitor (NNRTI; n = 141)-, or PI + NNRTI (n = 140)-based strategies with a median follow-up of 5 years.
METHODS: At baseline and 1-month (metabolic parameters only) and 4-month follow-up intervals, fat-free mass (FFM) and total body fat were calculated, anthropometric measurements were performed, and fasting metabolic parameters were obtained. Rates of change and mean change were compared.
RESULTS: The PI + NNRTI strategy resulted in greater increases in triglycerides and low-density lipoprotein cholesterol compared with the PI and the NNRTI strategies (P < 0.005), with no differences between the PI and NNRTI strategies. High-density lipoprotein cholesterol increased significantly more in the NNRTI strategy than in the PI strategy (P < 0.005). Insulin and insulin resistance increased similarly with all 3 strategies. Changes in total and regional body composition (loss of subcutaneous tissue area and gains in FFM, nonsubcutaneous tissue area, and visceral tissue area) were observed but did not differ by strategy.
CONCLUSIONS: Long-term follow-up of participants initiating 3 ART strategies demonstrated similar changes in total and regional fat, with no differences by ART strategy. The differential effects on lipid metabolism by strategy and the overall increases in insulin and insulin resistance with all 3 strategies necessitate close monitoring of patients on ART.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325603     DOI: 10.1097/QAI.0b013e31804216cf

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  34 in total

Review 1.  Dyslipidemia and its Treatment in HIV Infection.

Authors:  Carl Grunfeld
Journal:  Top HIV Med       Date:  2010 Aug-Sep

2.  Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Authors:  Takara L Stanley; Julian Falutz; Jean-Claude Mamputu; Graziella Soulban; Diane Potvin; Steven K Grinspoon
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

Review 3.  Biomarkers and HIV-associated cardiovascular disease.

Authors:  Jason V Baker; Daniel Duprez
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

4.  Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors.

Authors:  Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

Review 5.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

Review 6.  Adipose Tissue in HIV Infection.

Authors:  John R Koethe
Journal:  Compr Physiol       Date:  2017-09-12       Impact factor: 9.090

7.  Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.

Authors:  Itziar Frades; Ben Readhead; Letizia Amadori; Simon Koplev; Husain A Talukdar; Heidi M Crane; Paul K Crane; Jason C Kovacic; Joel T Dudley; Chiara Giannarelli; Johan L M Björkegren; Inga Peter
Journal:  Circ Genom Precis Med       Date:  2019-05-06

8.  Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.

Authors:  James H Stein; Lauren Komarow; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; Robert A Parker; Francesca J Torriani
Journal:  J Clin Lipidol       Date:  2008-12       Impact factor: 4.766

9.  Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study.

Authors:  Phyllis C Tien; Michael F E Schneider; Stephen R Cole; Alexandra M Levine; Mardge Cohen; Jack DeHovitz; Mary Young; Jessica E Justman
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-01       Impact factor: 3.731

Review 10.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.